Personalizing Asthma Management to Improve Control in Important Asthma Subpopulations Webcast

Original release date: December 2, 2014
Re-review date: January 25, 2016
Expiration date: January 25, 2017
Estimated time to complete: 1.0 hour

Faculty

Eli O. Meltzer, MD
Allergy & Asthma Medical Group & Research Center
Clinical Professor of Pediatrics
Division of Allergy and Immunology
University of California, San Diego

Program Overview

Asthma remains the most prevalent chronic illness in the United States today. The US Centers for Disease Control and Prevention estimates that 16.5 million adults and 6.1 million children and adolescents currently suffer from asthma. In large part, asthma can be treated successfully if managed and followed up by healthcare professionals appropriately.

However, healthcare providers may not give enough attention to difficult-to-treat cases of asthma in which patients have confounding factors that contribute to disease symptoms that are worse than in other individuals. These patients may require additional consideration for care. It has become increasingly evident that in order to prevent poor outcomes in these subpopulations, healthcare providers must individualize care in order to address specific patient needs.

Target Audience

This activity has been designed for primary care physicians, pediatricians, allied health professionals, and other healthcare providers involved in the treatment of patients with asthma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Individualize asthma management plans based on patient phenotype or other characteristics that influence disease burden
  • Discuss ways to encourage self-monitoring strategies and medication adherence for patients with asthma
  • Describe the use of structured interviews and validated assessment tools to evaluate asthma control in practice

Directions to Learner

There are no fees for participating and receiving CME credit for this activity. During the period January 25, 2016 through January 25, 2017, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest by recording the best answer to each question in the answer key on the evaluation form
  • Complete the evaluation form

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be sent to you within 4 weeks.

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Integrity Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Eli O. Meltzer, MD
Advisory Board/Consultant: Alcon, Alexza, AstraZeneca, Bausch + Lomb, Boehringer Ingelheim, Johnson & Johnson, Kalypsys, Meda, Merck, Mylan, Proctor & Gamble, Rigel, Sanofi, Sunovion, Teva
Grant/Research: Alcon, Amgen, Apotex, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, HRA, Kalypsys, MedImmune, Merck, Novartis, Ono, Rigel, Shionogi, Sunovion, Teva
Speaker: Alcon, Meda, Merck, Mylan, Sunovion, Teva

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Privacy Policy

When you participate in an online educational activity sponsored by Integrity CE, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and...(continued)

Minimum System Requirements

Windows XP, Windows 2000, Windows Vista, and Windows 7 Intel Pentium 4, 2.33 + GHz (or equivalent)
Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer is not recommended.

Mac OS X v10.4 or later
1.8GHz or faster (or equivalent)
Intel Core Duo 1.33GHz or faster (or equivalent)
Adobe® Flash® Player 10

Click here for more information on minimum system requirements.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

begin pretest

pre

For optimal performance, the use of Internet Explorer is not recommended.

 

integrity

Sponsored by Integrity Continuing Education, Inc.